August 23, 2021
FDA grants full approval to Pfizer-BioNTech COVID-19 vaccine
Editor's Note
The Food and Drug Administration on August 23 announced that it had approved the first COVID-19 vaccine, known as Pfizer-BioNTech.
The vaccine will now be marketed as Comirnaty, for the prevention of COVID-19 in those 16 years of age and older.
The vaccine will continue to be available under emergency use authorization for those 12 through 15 years of age and for the administration of a third dose in immunocompromised individuals.
Full approval may now instill confidence in the vaccine for those who are not vaccinated, the FDA says.
Free Daily News
- AI boosts accuracy in surgical reports, outperforming surgeons
- AI models improve prediction of surgical complications using preoperative clinical notes
- Ambient AI healthcare documentation gains traction as capabilities expand
- Healthcare M&A faces tighter review as FTC retains guidelines
- Healthcare giants prioritize shareholder payouts over patient care
- Texas abortion ban linked to spike in pregnancy complications, maternal death
- AI streamlines documentation, frees time for nurses at Cedars-Sinai surgical unit
- Study identifies potential non-surgical treatment for inguinal hernias
- Rural hospital closures remain a growing concern despite slight financial improvement
- Session: Hoisting the Sails—Winning Strategies for Growing Service Lines in an ASC
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement